#1 Clinical Trials Search in Europe

Calcium Levofolinate

Calcium levofolinate, also known as levofolinic acid, is a drug being studied in various clinical trials for its potential to enhance the effectiveness of cancer treatments. This article explores how calcium levofolinate is being used in combination with other drugs to treat different types of cancer, including pancreatic, colorectal, and gastric cancers.

Table of Contents

What is Calcium Levofolinate?

Calcium levofolinate, also known as levofolinic acid, is a medication used in cancer treatment[1]. It is a form of folic acid, a vitamin that plays a crucial role in cell growth and division. In cancer therapy, calcium levofolinate is often used to enhance the effectiveness of other chemotherapy drugs.

Uses of Calcium Levofolinate

Calcium levofolinate is primarily used in the treatment of various types of cancer, including:

  • Colorectal Cancer: It is used in the treatment of metastatic colorectal cancer (cancer that has spread from the colon or rectum to other parts of the body)[1].
  • Pancreatic Cancer: Calcium levofolinate is used in the treatment of pancreatic ductal adenocarcinoma, a type of pancreatic cancer[2].
  • Gastric Cancer: It is also used in the treatment of advanced gastric cancer (cancer of the stomach) and adenocarcinoma of the esophagogastric junction (cancer where the esophagus meets the stomach)[3].

Combination Therapies

Calcium levofolinate is rarely used alone. Instead, it is typically combined with other chemotherapy drugs to create more effective treatment regimens. Some common combinations include:

  • FOLFIRI: This regimen combines calcium levofolinate with fluorouracil (5-FU) and irinotecan[1].
  • FOLFOX: In this combination, calcium levofolinate is used with fluorouracil and oxaliplatin[3].
  • mFOLFIRINOX: This is a modified version of FOLFIRINOX, which includes calcium levofolinate, fluorouracil, irinotecan, and oxaliplatin[2].

These combinations are designed to attack cancer cells in multiple ways, potentially increasing the effectiveness of the treatment.

How is Calcium Levofolinate Administered?

Calcium levofolinate is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency can vary depending on the specific treatment regimen and the patient’s individual needs. For example:

  • In some regimens, it may be given at a dose of 200 mg/m² every 14 days[4].
  • In others, it might be administered at 100 mg/m² on the first day of each 14-day cycle[2].

The administration is usually part of a larger chemotherapy session that includes other drugs.

Potential Side Effects

While calcium levofolinate itself is generally well-tolerated, patients may experience side effects from the combination chemotherapy regimens it’s used in. These can include:

  • Nausea and vomiting
  • Diarrhea
  • Fatigue
  • Decreased blood cell counts, which can increase the risk of infection or bleeding
  • Hair loss

It’s important to discuss potential side effects with your healthcare provider, as they can provide guidance on managing these symptoms[2].

Ongoing Research

Calcium levofolinate continues to be studied in various clinical trials to improve cancer treatment outcomes. Researchers are investigating its use in different combinations and for various types of cancer. For example:

  • A study is looking at combining calcium levofolinate-based chemotherapy with a new drug called NP137 for pancreatic cancer[2].
  • Another trial is comparing different calcium levofolinate-containing regimens (mFOLFOX, mFOLFIRI, and FOLFPTX) for gastric cancer[3].

These ongoing studies aim to find more effective ways to use calcium levofolinate in cancer treatment, potentially leading to better outcomes for patients in the future.

Aspect Details
Drug Combinations Calcium levofolinate is studied in combination with 5-FU, oxaliplatin, irinotecan, and other drugs
Cancer Types Pancreatic cancer, colorectal cancer, advanced gastric cancer
Administration Intravenous infusion, typically as part of chemotherapy regimens
Primary Outcomes Progression-free survival, overall survival, safety and tolerability
Secondary Outcomes Objective response rate, quality of life, pharmacokinetics
Trial Phases Phase II and Phase III studies are ongoing
Treatment Duration Varies by trial, often until disease progression or unacceptable toxicity

FAQ

  • What is calcium levofolinate? Calcium levofolinate is a form of folic acid used in cancer treatment. It helps enhance the effects of certain chemotherapy drugs, particularly 5-fluorouracil (5-FU).
  • In which types of cancer is calcium levofolinate being studied? Clinical trials are investigating the use of calcium levofolinate in various cancers, including pancreatic cancer, colorectal cancer, and advanced gastric cancer.
  • How is calcium levofolinate typically administered? Calcium levofolinate is usually given intravenously (through a vein) as part of a combination chemotherapy regimen. The dosage and frequency can vary depending on the specific treatment protocol.
  • What are some common drug combinations that include calcium levofolinate? Common combinations include FOLFOX (with oxaliplatin and 5-FU), FOLFIRI (with irinotecan and 5-FU), and FOLFIRINOX (with oxaliplatin, irinotecan, and 5-FU).
  • What are researchers hoping to achieve by using calcium levofolinate in these trials? Researchers aim to improve treatment outcomes, such as progression-free survival, overall survival, and tumor response rates, while maintaining an acceptable safety profile for patients with various types of cancer.

Ongoing Clinical Trials on Calcium Levofolinate

  • Study on the Effectiveness of FOLFIRINOX and FOLFOX for Patients with Advanced Small Bowel Cancer Using Calcium Levofolinate, Irinotecan, and Oxaliplatin

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy

  • Postoperative oxaliplatin liver‑directed chemotherapy plus drug combination in patients with resected colorectal liver metastases at high risk of recurrence

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study of drug combination with radiotherapy versus radiotherapy alone for locally advanced rectal cancer in patients 75 years and older

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Comparing drug combinations with panitumumab for patients with RAS and B-RAF wild-type metastatic colorectal cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Study on FOLFOX and Docetaxel for Patients with Advanced or Metastatic Stomach and Esophagus Cancer

    Not recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of Magrolimab with Bevacizumab and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Belgium France Germany Italy Spain

Glossary

  • Calcium levofolinate: A form of folic acid used in cancer treatment to enhance the effects of certain chemotherapy drugs, particularly 5-fluorouracil (5-FU).
  • 5-Fluorouracil (5-FU): A chemotherapy drug commonly used in the treatment of various cancers, often in combination with calcium levofolinate.
  • FOLFOX: A chemotherapy regimen that combines oxaliplatin, fluorouracil, and calcium levofolinate.
  • FOLFIRI: A chemotherapy regimen that combines irinotecan, fluorouracil, and calcium levofolinate.
  • FOLFIRINOX: A chemotherapy regimen that combines oxaliplatin, irinotecan, fluorouracil, and calcium levofolinate.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Metastatic cancer: Cancer that has spread from its original site to other parts of the body.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • Quality of Life (QoL): A measure of an individual's well-being and ability to perform daily activities, often assessed in cancer clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT04776655
  2. https://clinicaltrials.gov/study/NCT05546853
  3. https://clinicaltrials.gov/study/NCT03045770
  4. https://clinicaltrials.gov/study/NCT02697058